• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

LCZ696治疗高血压的疗效与安全性的Meta分析

A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension.

作者信息

Zheng Li, Xia Binbin, Zhang Xuqian, Zhao Yan

机构信息

Department of Pharmacy, China Aerospace Science & Industry Corporation 731 Hospital, Beijing 100074, China.

Department of Pharmacy, Luhe Hospital, Beijing 101149, China.

出版信息

Cardiol Res Pract. 2021 Mar 20;2021:8867578. doi: 10.1155/2021/8867578. eCollection 2021.

DOI:10.1155/2021/8867578
PMID:33824765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8007371/
Abstract

OBJECTIVES

To systematically evaluate the differences in effect and safety of LCZ696 and angiotensin receptor blockers (ARBs) in the treatment of hypertension.

METHODS

We searched PubMed, Cochrane, Web of Science, and Ovid, collected randomized controlled trials (RCTs) about the effect and safety of LCZ696 and ARBs in hypertensive patients, extracted relevant data and evaluated the quality of the included literature according to the RCT quality evaluation standard recommended by Cochrane Reviewer's Handbook, using RevMan 5.3, and performed meta-analysis.

RESULTS

Eight RCTs studies were included, with a total of 4313 patients. Compared with ARBs, LCZ696 can better reduce systolic blood pressure (msSBP) (WMD -4.29 mmHg; 95% CI: -5.37 to -3.21;  < 0.001), diastolic blood pressure (msDBP) (WMD -1.87 mmHg; 95% CI:-2.38 to -1.36;  < 0.01), ambulatory systolic blood pressure (maSBP) (WMD -3.37 mmHg; 95% CI:-4.26 to -2.47;  < 0.01), and ambulatory diastolic blood pressure (maDBP) (WMD -1.47 mmHg; 95% CI: -1.97 to -0.97;  < 0.01). In terms of safety, LCZ696 is basically the same as ARBs, but LCZ696 is more likely to cause cough than ARBs (OR = 2.38; 95% CI: 1.27 to 4.47;  < 0.01).

CONCLUSION

LCZ696 can significantly reduce the blood pressure level of patients with hypertension, but it is necessary to pay attention to whether the patient will experience coughing after taking the drug.

摘要

目的

系统评价LCZ696与血管紧张素受体阻滞剂（ARB）治疗高血压的疗效及安全性差异。

方法

检索PubMed、Cochrane、Web of Science和Ovid，收集关于LCZ696与ARB治疗高血压患者疗效及安全性的随机对照试验（RCT），提取相关数据，并根据Cochrane系统评价员手册推荐的RCT质量评价标准，采用RevMan 5.3对纳入文献质量进行评价并进行Meta分析。

结果

共纳入8项RCT研究，总计4313例患者。与ARB相比，LCZ696能更好地降低收缩压（平均收缩压，msSBP）（加权均数差[WMD] -4.29 mmHg；95%置信区间[CI]：-5.37至-3.21；P<0.001）、舒张压（平均舒张压，msDBP）（WMD -1.87 mmHg；95% CI：-2.38至-1.36；P<0.01）、动态收缩压（动态平均收缩压，maSBP）（WMD -3.37 mmHg；95% CI：-4.26至-2.47；P<0.01）和动态舒张压（动态平均舒张压，maDBP）（WMD -1.47 mmHg；95% CI：-1.97至-0.97；P<0.01）。在安全性方面，LCZ696与ARB基本相同，但LCZ696比ARB更易引起咳嗽（比值比[OR]=2.38；95% CI：1.27至4.47；P<0.01）。

结论

LCZ696能显著降低高血压患者血压水平，但需注意患者服药后是否会出现咳嗽。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/4446beb49b82/CRP2021-8867578.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/5b3f1929b386/CRP2021-8867578.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/ed3dfbf9d749/CRP2021-8867578.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/15d87d915e4f/CRP2021-8867578.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/3d9cd6b91648/CRP2021-8867578.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/d8ed58232e41/CRP2021-8867578.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/41a6765d7b81/CRP2021-8867578.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/4446beb49b82/CRP2021-8867578.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/5b3f1929b386/CRP2021-8867578.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/ed3dfbf9d749/CRP2021-8867578.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/15d87d915e4f/CRP2021-8867578.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/3d9cd6b91648/CRP2021-8867578.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/d8ed58232e41/CRP2021-8867578.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/41a6765d7b81/CRP2021-8867578.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f5/8007371/4446beb49b82/CRP2021-8867578.007.jpg

相似文献

1
A Meta-Analysis on the Effect and Safety of LCZ696 in the Treatment of Hypertension.LCZ696治疗高血压的疗效与安全性的Meta分析
Cardiol Res Pract. 2021 Mar 20;2021:8867578. doi: 10.1155/2021/8867578. eCollection 2021.
2
The Antihypertensive Effects and Safety of LCZ696 in Patients with Hypertension: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.LCZ696对高血压患者的降压效果及安全性：随机对照试验的系统评价和荟萃分析
J Clin Med. 2021 Jun 26;10(13):2824. doi: 10.3390/jcm10132824.
3
Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies.LCZ696治疗高血压的疗效与安全性：9项随机对照试验的荟萃分析
Medicine (Baltimore). 2019 Jul;98(28):e16093. doi: 10.1097/MD.0000000000016093.
4
Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials.LCZ696 与 ARBs 短期治疗原发性高血压的疗效和安全性比较：一项随机对照试验的荟萃分析。
J Cardiovasc Pharmacol. 2021 May 1;77(5):650-659. doi: 10.1097/FJC.0000000000001001.
5
Anti-Hypertensive Effect of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials.沙库巴曲缬沙坦的降压作用：随机对照试验的荟萃分析
Cardiol Res. 2019 Feb;10(1):24-33. doi: 10.14740/cr813. Epub 2019 Feb 24.
6
The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials.与血管紧张素受体阻滞剂相比，LCZ696对高血压患者的影响：一项随机对照试验的荟萃分析
J Cardiovasc Pharmacol Ther. 2017 Sep;22(5):447-457. doi: 10.1177/1074248417693379. Epub 2017 Mar 2.
7
Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials.LCZ696（沙库巴曲缬沙坦）对高血压患者血压的影响：一项随机对照试验的荟萃分析。
Cardiology. 2020;145(9):589-598. doi: 10.1159/000507327. Epub 2020 Jul 29.
8
Chronotherapy of Hypertension with Angiotensin Receptor Blockers-A Meta-Analysis of Blood Pressure Measured by Ambulatory Blood Pressure Monitoring in Randomized Trials.血管紧张素受体阻滞剂治疗高血压的时间治疗学：一项随机试验中动态血压监测的血压测量的荟萃分析。
Am J Med Sci. 2021 Jan;361(1):36-42. doi: 10.1016/j.amjms.2020.07.031. Epub 2020 Jul 28.
9
Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials.血管紧张素转换酶抑制剂与血管紧张素 II 受体拮抗剂对高血压患者胰岛素敏感性的影响：一项随机对照试验的荟萃分析。
PLoS One. 2021 Jul 7;16(7):e0253492. doi: 10.1371/journal.pone.0253492. eCollection 2021.
10
Pharmacological interventions for hypertension in children.儿童高血压的药物干预措施。
Evid Based Child Health. 2014 Sep;9(3):498-580. doi: 10.1002/ebch.1974.

引用本文的文献

1
Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension.网络荟萃分析沙库巴曲缬沙坦治疗原发性高血压。
Clin Res Cardiol. 2023 Jul;112(7):855-867. doi: 10.1007/s00392-022-02120-0. Epub 2022 Nov 3.
2
Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.沙库巴曲缬沙坦对射血分数保留的心力衰竭的疗效和安全性：一项随机对照试验的荟萃分析。
Front Cardiovasc Med. 2022 Sep 8;9:897423. doi: 10.3389/fcvm.2022.897423. eCollection 2022.
3
The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.

本文引用的文献

1
Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction.缺血性心脏病病理生理学范式概述：从斑块激活到微血管功能障碍。
Int J Mol Sci. 2020 Oct 30;21(21):8118. doi: 10.3390/ijms21218118.
2
Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist.晚期心力衰竭与终末期心力衰竭：二者是否存在差异？
Diagnostics (Basel). 2019 Nov 1;9(4):170. doi: 10.3390/diagnostics9040170.
3
The Evolution from Hypertension to Heart Failure.从高血压到心力衰竭的演变。
沙库巴曲缬沙坦与缬沙坦对高血压合并慢性心力衰竭患者血管内皮功能、脂联素、MMP-9 和 BNP 水平的影响比较。
J Healthc Eng. 2022 Feb 18;2022:9494981. doi: 10.1155/2022/9494981. eCollection 2022.
Heart Fail Clin. 2019 Oct;15(4):447-453. doi: 10.1016/j.hfc.2019.06.005. Epub 2019 Aug 7.
4
Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.死亡率、发病率和风险因素在中国及其省份，1990-2017 年：2017 年全球疾病负担研究的系统分析。
Lancet. 2019 Sep 28;394(10204):1145-1158. doi: 10.1016/S0140-6736(19)30427-1. Epub 2019 Jun 24.
5
Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.沙库巴曲缬沙坦与奥美沙坦治疗亚洲原发性高血压患者的疗效和安全性比较：一项随机、双盲、为期8周的研究。
J Clin Hypertens (Greenwich). 2019 Jan;21(1):67-76. doi: 10.1111/jch.13437. Epub 2018 Dec 11.
6
Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy.沙库巴曲缬沙坦在心血管疾病中的应用：迄今的证据及在治疗中的地位
Ther Adv Cardiovasc Dis. 2018 Aug;12(8):217-231. doi: 10.1177/1753944718784536. Epub 2018 Jun 19.
7
Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction : A retrospective cohort study.沙库巴曲缬沙坦用于左心室射血分数降低的心力衰竭：一项回顾性队列研究。
Herz. 2019 Aug;44(5):425-432. doi: 10.1007/s00059-017-4671-1. Epub 2018 Jan 19.
8
Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.沙库巴曲缬沙坦治疗奥美沙坦治疗未控制的原发性高血压的疗效和安全性：一项随机、双盲、8 周研究。
J Clin Hypertens (Greenwich). 2018 Jan;20(1):150-158. doi: 10.1111/jch.13153. Epub 2018 Jan 16.
9
Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension.沙库巴曲缬沙坦在动脉高血压治疗中除控制血压之外的优势。
Eur Heart J. 2017 Nov 21;38(44):3318-3320. doi: 10.1093/eurheartj/ehx560.
10
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.沙库巴曲缬沙坦对比奥美沙坦对原发性高血压患者心血管重构的影响：一项随机、双盲、阳性对照研究的结果。
Eur Heart J. 2017 Nov 21;38(44):3308-3317. doi: 10.1093/eurheartj/ehx525.